



Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

SEP 14 2004

Mr. Robert Eusebio
Manager Regulatory Affairs
Dade MicroScan, Inc.
1584 Enterprise Boulevard
West Sacramento, CA 95691

Re: k023202
Trade/Device Name: MicroScan[®] Synergies plus[™] Dried Gram-Negative MIC/Combo
Panels with Cefpodoxime (0.015-64 µg/ml) and Ceftazidime
(0.5-64 µg/ml)
Regulation Number: 21 CFR 866.1640
Regulation Name: Antimicrobial susceptibility test powder
Regulatory Class: Class II
Product Code: JWY
Dated: July 30, 2004
Received: August 3, 2004

Dear Mr. Eusebio:

This letter corrects our substantially equivalent letter of October 23, 2002, regarding the trade name which was changed to MicroScan[®] Synergies Plus to better reflect the intended use of the device.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent [(for the indications for use stated in the enclosure)] to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-3084. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at their toll free number (800) 638-2041 or at (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Sally A. Hojvat", with a stylized flourish at the end.

Sally A. Hojvat, M.Sc., Ph.D.

Director

Division of Microbiology Devices

Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): K023202

Device Name: MicroScan® Synergies plus™ Dried Gram-Negative MIC/Combo Panels with Cefpodoxime (0.015-64 µg/ml) and Ceftazidime (0.5-64 µg/ml)

Indications For Use:

The MicroScan® Synergies plus™ Dried Gram-Negative MIC/Combo Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility for Gram-Negative organisms and screening for suspected ESBL production in *E. coli*, *K. oxytoca* and *K. pneumoniae*. After inoculation, panels are incubated for a minimum of 16 hours at 35°C in a non-CO₂ incubator, and read visually, according to the Package Insert.

This particular submission is for the antimicrobials cefpodoxime (0.015-64 µg/ml) and ceftazidime (0.5-64 µg/ml).

The Gram-Negative organisms which may be used for screening for suspected ESBL production in this panel are:

Escherichia coli
Klebsiella oxytoca
Klebsiella pneumoniae


Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)



Division Sign-Off

Page 1 of 1

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K02320